Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. NovoCure Ltd shares valued at $734 were sold by Paravasthu Mukund on Nov 02 ’24. At $16.69 per share, Paravasthu Mukund sold 44 shares. The insider’s holdings dropped to 3,459 shares worth approximately $0.11 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Puri Michal Nath sold 810 shares, netting a total of over 12,792 in proceeds. Following the sale of shares at $15.79 each, the insider now holds 110,093 shares.
Before that, Leonard Frank X had sold 598 shares from its account. In a trade valued at $9,531, the EVP, Pres., Novocure Oncology traded NovoCure Ltd shares for $15.94 each. Upon closing the transaction, the insider’s holdings decreased to 598 shares, worth approximately $5.09 million.
As published in a research note from Evercore ISI on December 02, 2024, NovoCure Ltd [NVCR] has been rated up from an In-line to an Outperform and the price target has been revised to $30 from $18. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid October. Earlier on August 28, 2023, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for NVCR stock which previously was a “a Buy”.
Analyzing NVCR Stock Performance
During the last five days, there has been a surge of approximately 1.32%. Over the course of the year, NovoCure Ltd shares have jumped approximately 111.25%. Shares of the company reached a 52-week high of $34.13 on 12/18/24 and a 52-week low of $11.70 on 04/23/24. A 50-day SMA is recorded $20.41, while a 200-day SMA reached $18.14. Nevertheless, trading volume fell to 1.81 million shares from 0.99 million shares the previous day.
Support And Resistance Levels for NovoCure Ltd (NVCR)
According to the 24-hour chart, there is a support level at 30.04, which, if violated, would cause prices to drop to 28.53. In the upper region, resistance lies at 33.59. The next price resistance is at 35.63. RSI (Relative Strength Index) is 67.63 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.33, which suggests the price will increase in the coming days. Percent R is at 17.79%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
